<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005994</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067996</org_study_id>
    <secondary_id>URCC-3996</secondary_id>
    <secondary_id>NCI-P00-0160</secondary_id>
    <nct_id>NCT00005994</nct_id>
  </id_info>
  <brief_title>Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>Patient Information and Antiemetic Drug Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <brief_summary>
    <textblock>
      RATIONALE: Patient education may improve the effectiveness of ondansetron in preventing
      nausea and vomiting in patients receiving chemotherapy.

      PURPOSE: This randomized clinical trial is studying how well patient education works in
      preventing nausea and vomiting in cancer patients receiving chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether an educational intervention to enhance the effectiveness of
      ondansetron can prevent acute postchemotherapy nausea and emesis in cancer patients. II.
      Assess any potential effectiveness of the intervention on delayed postchemotherapy nausea and
      emesis in these patients. III. Examine the effect of the intervention on patient
      expectations.

      OUTLINE: This is a randomized, double blind, multicenter study. Patients are stratified by
      center and chemotherapy agent (cisplatin vs carboplatin vs doxorubicin). Patients are
      randomized to one of two treatment arms. Arm I: Patients receive standard educational
      materials. Arm II: Patients receive specific intervention material in addition to standard
      educational materials. Patients then complete a patient information questionnaire. Patients
      receive ondansetron orally or IV over 10-15 minutes in addition to the first 2 courses of
      chemotherapy. Patients complete a nausea and emesis questionnaire after each of their first 2
      chemotherapy treatments.

      PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
  </study_design_info>
  <condition>Nausea and Vomiting</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Chemotherapy naive with diagnosis of any cancer scheduled to
        receive chemotherapy containing cisplatin, carboplatin, or doxorubicin

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified

        PRIOR CONCURRENT THERAPY: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary R. Morrow, PhD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southeast Cancer Control Consortium</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104-4241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>June 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2004</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Gary Morrow</investigator_full_name>
    <investigator_title>Director, URCC CCOP Research Base</investigator_title>
  </responsible_party>
  <keyword>nausea and vomiting</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

